BlackRock’s Windtree Therapeutics WINT Stock Holding History

BlackRock’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Hold	0	–	-$2	–	5525
2024 Q4	–	Hold	0	–	–	–	5387
2022 Q2	–	Sell	-1	Closed	-$56K	–	6002
2022 Q1	$56K	Hold	1	–	–	﹤0.01%	5402
2021 Q4	$82K	Hold	1	–	–	﹤0.01%	5320
2021 Q3	$102K	Hold	1	–	–	﹤0.01%	5132
2021 Q2	$132K	Buy	+1	New	+$97.3K	﹤0.01%	4981

Other funds holding WINT

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

BlackRock's WINT Position: Q1 2025 in Review

BlackRock held its Windtree Therapeutics (WINT) position steady in Q1 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5525.

BlackRock first reported a position in WINT in Q2 2021 and has held it in 4 quarters since. The position peaked at $132K in Q2 2021. 5 funds tracked by Wall St. Rank hold WINT as of Q1 2025.

BlackRock held 0 shares of Windtree Therapeutics worth $0 as of Q1 2025.
BlackRock left its Windtree Therapeutics share count unchanged in Q1 2025.
Windtree Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2025, its #5525 holding.
BlackRock first reported a position in Windtree Therapeutics in Q2 2021 and has held it in 4 quarters since.
BlackRock's Windtree Therapeutics position peaked at $132K in Q2 2021.
5 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2025.

Based on BlackRock's 13F filing for Q1 2025, filed 2 May 2025.